A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 681-691

  Fan, Xuejun ^a   Brezski, Randall J ^b,c   Deng, Hui ^a   Dhupkar, Pooja M ^a   Shi, Yun ^a   Gonzalez, Anneliese ^a   Zhang, Songlin ^a   Rycyzyn, Michael ^b   Strohl, William R ^b   Jordan, Robert E ^b   Zhang, Ningyan ^a   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Janssen   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; EPITOPE; MAB 2095 2; MATRIX METALLOPROTEINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; MCF 7 CELL LINE; METABOLISM; NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASES; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASMS; PROTEOLYSIS; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84954128572     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0715     Document Type: Article

References (36)

1. An Z. Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 2010;1:319-30.
2. Reichert JM. Antibodies to watch in 2013: mid-year update. MAbs 2013;5:513-7.
3. Strohl WR. Therapeutic monoclonal antibodies: past, present, and future. In:An Z, editor. Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, NJ: John Wiley & Sons, Inc.; 2009. p. 889.
4. Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012; 14:R116.
5. Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 2013;13:223-32.
6. Ratti M, Tomasello G. Emerging combination therapies to overcome resistance in EGFR-driven tumors. Anti-cancer Drugs 2014;25: 127-39.
7. Thery JC, Spano JP, Azria D, Raymond E, Penault Llorca F. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 2014;50:892-901.
8. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27.
9. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogrammingin"resistant"breast carcinoma cells. Cancer Res 2009;69:2191-4.
10. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008;3:e3065.
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
12. Shattuck DL, Miller JK, Carraway KL III, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008;68:1471-7.
13. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.
14. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999;27:1533-41.
15. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005;11: 4898-904.
16. Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009;106:17864-9.
17. Malia TJ, Teplyakov A, Brezski RJ, Luo J, Kinder M, Sweet RW, et al. Structure and specificity of an antibody targeting a proteolytically-cleaved IgG hinge. Proteins 2014;82:1656-67.
18. Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, McCarthy SG, et al. Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 2013;288:30843-54.
19. Huang Z, Choi BK, Mujoo K, Fan X, Fa M, Mukherjee S, et al. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene 2014;56:1-11.
20. Zhang N, Liu L, Dan Dumitru C, Cummings NR, Cukan M, Jiang Y, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzu-mab in preclinical study. MAbs 2011;3:289-98.
21. Porter RR. Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature 1958;182: 670-1.
22. Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science 1960;132:1770-1.
23. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008;45:1837-46.
24. Gearing AJ, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, et al. Selective cleavage of human IgG by the matrix metalloproteinases, matri-lysin and stromelysin. Immunol Lett 2002;81:41-8.
25. von Pawel-Rammingen U, Johansson BP, Bjorck L. Ide S, a novel strepto-coccal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002;21:1607-15.
26. Mehta SK, Plaut AG, Calvanico NJ, Tomasi TB Jr. Human immunoglobulin A: production of an Fc fragment by an enteric microbial proteolytic enzyme. J Immunol 1973;111:1274-6.
27. Senior BW, Woof JM. Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases. Infect Immun 2005;73:1515-22.
28. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
29. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
30. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Breast Cancer Special Feature: leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012;109:2796-801.
31. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer development. Trends Cell Biol 2002;12:209-11.
32. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymaltransitioninbreastcancer.JMammaryGland BiolNeoplasia 2010;15:201-12.
33. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013;34:2041-51.
34. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs 2010;2:212-20.
35. von Pawel-Rammingen U. Streptococcal IdeS and its impact on immune response and inflammation. J Innate Immun 2012;4:132-40.
36. Schmidt A, DeRiggi D, Jordan RE, Whitaker B, Heavner GA, Kruszynski M. A synthetic peptide approach for elucidating the points of natural autoantibody reactivity to proteolytic fragments of human IgG. Adv Exp Med Biol 2009;611:411-2.